Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries

Launched by ZAGAZIG UNIVERSITY · Dec 31, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how magnesium sulphate can help protect the brain of babies who are born prematurely, specifically those born before 34 weeks of pregnancy. Research has shown that giving magnesium sulphate to mothers at risk of early delivery can reduce the chances of serious brain problems and movement difficulties in their children. This trial is looking for pregnant women who are between 24 and 33 weeks along and are expected to give birth within the next 24 hours. This includes women with multiple pregnancies (like twins or triplets), which carry a higher risk of complications.

If you or a loved one is eligible and chooses to participate, you will receive magnesium sulphate before delivery. This treatment is aimed at improving the baby's chances of healthy brain development and reducing the risk of conditions like cerebral palsy. It’s important to note that women with certain health conditions, such as allergies to magnesium or kidney problems, may not be able to participate. Overall, this trial is a crucial step in understanding how to protect vulnerable babies during premature births.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Women at risk of preterm birth who are between 24+0 and 33+6 weeks of gestation.
• 2. When early preterm birth is planned or expected within 24 h, regardless of:
• • Plurality or parity
• • Reason for the risks of preterm birth
• • Anticipated mode of birth
• • Whether antenatal corticosteroids have been given or not
• Exclusion Criteria:
• • Women with known Hypersensitivity to magnesium
• • Caution regarding dosage for patients with renal impairment
• • Preterm delivery after 34 weeks